The impact of institutional measures on optimal use of intravenous immunoglobulin.
IVIG
institutional measures
patient blood management
transfusion medicine
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
17 Oct 2024
17 Oct 2024
Historique:
revised:
06
09
2024
received:
31
12
2023
accepted:
16
09
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
aheadofprint
Résumé
Intravenous immunoglobulin (IVIG) shortage represents an emerging issue in transfusion medicine. Limited data are available to determine effective strategies for optimal use. The objective of this retrospective observational study was to determine the impact of institutional measures on IVIG use at a large academic center. IVIG infusions from November 26, 2018 to September 25, 2022 were categorized according to their appropriateness (Recommended, Option of treatment, or Unrecommended), based on provincial guidelines, and separated into three phases: Reference, Transition, and Post-Implementation phases, the latter following the adoption of restrictive measures, including mandatory standardized order forms, a blood bank gatekeeping strategy, and the creation of a stewardship committee. A total of 5431 IVIG infusions were administered to 544 patients, accounting for 295,033 g. The most common indication categories were neurology (30.4%), immunology (29.0%), and hematology (17.4%). From Reference to Post-Implementation phase, IVIG infusions decreased from 2275 to 2000 with unrecommended indications dropping from 9.5% to 7.4% (p = 0.01), and a global reduction of 23.0% (from 131,163 g to 100,936 g of IVIG). Decrease in chronic immunomodulation accounted for 48.3% of total reduction (14,610 g of 30,227 g), whereas single-use immunomodulation, 40.5% (12,237 g of 30,227 g). Moreover, an absolute reduction of 16.9% was observed in orders exceeding the recommended doses (20.8% to 3.9%; p < 0.0001). Together, the unrecommended and excessive IVIG doses decreased from 19,975 g (15.2%) to 6670 g (6.6%). A global reduction in IVIG use and a preferential decrease in the unrecommended orders were observed, most likely attributable to the bundle of restrictive strategies implemented.
Sections du résumé
BACKGROUND
BACKGROUND
Intravenous immunoglobulin (IVIG) shortage represents an emerging issue in transfusion medicine. Limited data are available to determine effective strategies for optimal use. The objective of this retrospective observational study was to determine the impact of institutional measures on IVIG use at a large academic center.
METHODS
METHODS
IVIG infusions from November 26, 2018 to September 25, 2022 were categorized according to their appropriateness (Recommended, Option of treatment, or Unrecommended), based on provincial guidelines, and separated into three phases: Reference, Transition, and Post-Implementation phases, the latter following the adoption of restrictive measures, including mandatory standardized order forms, a blood bank gatekeeping strategy, and the creation of a stewardship committee.
RESULTS
RESULTS
A total of 5431 IVIG infusions were administered to 544 patients, accounting for 295,033 g. The most common indication categories were neurology (30.4%), immunology (29.0%), and hematology (17.4%). From Reference to Post-Implementation phase, IVIG infusions decreased from 2275 to 2000 with unrecommended indications dropping from 9.5% to 7.4% (p = 0.01), and a global reduction of 23.0% (from 131,163 g to 100,936 g of IVIG). Decrease in chronic immunomodulation accounted for 48.3% of total reduction (14,610 g of 30,227 g), whereas single-use immunomodulation, 40.5% (12,237 g of 30,227 g). Moreover, an absolute reduction of 16.9% was observed in orders exceeding the recommended doses (20.8% to 3.9%; p < 0.0001). Together, the unrecommended and excessive IVIG doses decreased from 19,975 g (15.2%) to 6670 g (6.6%).
CONCLUSIONS
CONCLUSIONS
A global reduction in IVIG use and a preferential decrease in the unrecommended orders were observed, most likely attributable to the bundle of restrictive strategies implemented.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Briand S, Trudeau M. Utilisation des immunoglobulines non spécifiques intraveineuses et sous‐cutanées au Québec 2019–2020. INSPQ. 2021. https://www.inspq.qc.ca/publications/2823
Hema‐Quebec. Every gesture counts. Annual report 2019–2020. 2020. https://www.hema-quebec.qc.ca/userfiles/file/RA-2019-2020/02/Hema-Quebec_2019-2020_Annual_Report.pdf
Hema‐Quebec. Going beyond and above for Quebecers. Annual report 2022–2023. 2023. https://www.hema‐quebec.qc.ca/userfiles/file/media/anglais/publications/HQ‐RA2022‐2023‐EN.pdf
Government of Canada. Final report of the expert panel on immune globulin product supply and related impacts in Canada. 2018. https://www.canada.ca/en/health‐canada/programs/expert‐panel‐immune‐globulin‐product‐supply‐related‐impacts‐canada.html
Feasby TE, Quan H, Tubman M, Pi D, Tinmouth A, So L, et al. Appropriateness of the use of intravenous immune globulin before and after the introduction of a utilization control program. Open Med. 2012;6(1):e28–e34.
National Advisory Committee on Blood and Blood Products. The National Plan for Management of Shortages of immunoglobulin products (Ig)—interim guidance. 2020. https://nacblood.ca/en/blood-shortage
INESSS. Optimal use guide ‐ Use of IVIg in neurology. 2017. https://www.inesss.qc.ca/en/publications/publications/publication/optimal‐use‐of‐immunoglobulin.html
INESSS. Optimal use guide ‐ Use of IVIg in hematology. 2020. https://www.inesss.qc.ca/en/publications/publications/publication/optimal-use-of-immunoglobulin.html
INESSS. Optimal use guide ‐ Use of IVIg and SCIg in clinical immunology. 2020. https://www.inesss.qc.ca/en/publications/publications/publication/optimal-use-of-immunoglobulin.html
INESSS. Optimal use guide ‐ Use of IVIg in dermatology. 2020. https://www.inesss.qc.ca/en/publications/publications/publication/optimal‐use‐of‐immunoglobulin.html
INESSS. Optimal use guide ‐ Use of IVIg in rheumatology. 2021. https://www.inesss.qc.ca/en/publications/publications/publication/optimal-use-of-immunoglobulin.html
INESSS. Optimal use guide ‐ Use of IVIg in infectious diseases. 2021. https://www.inesss.qc.ca/en/publications/publications/publication/optimal-use-of-immunoglobulin.html
INESSS. Optimal use guide ‐ Use in solid organ transplant. 2022. https://www.inesss.qc.ca/en/publications/publications/publication/optimal‐use‐of‐immunoglobulin.html
INESSS. Optimal use guide ‐ Use of IVIg and SCIg in fertility, cardiology and other indications. 2022. https://www.inesss.qc.ca/en/publications/publications/publication/optimal‐use‐of‐immunoglobulin.html
Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–178.
Pendergrast J, Armali C, Callum J, Cserti‐Gazdewich C, Jiwajee A, Lieberman L, et al. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin‐mediated hemolysis. Transfusion. 2021;61(4):1053–1063.
Vecchietti G, Kerl K, Prins C, Kaya G, Saurat J‐H, French LE. Severe eczematous skin reaction after high‐dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142(2):213–217.
Fakhouri F. Intravenous immunoglobulins and acute renal failure: mechanism and prevention. Rev Med Interne. 2007;28Spec No 1:4–6.
INSPQ. Utilisation des immunoglobulines non spécifiques intraveineuses et sous‐cutanées au Québec 2018–2019. 2020.
Constantine MM, Thomas W, Whitman L, Kahwash E, Dolan S, Smith S, et al. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic collaborative intravenous immune globulin utilization working group. Transfusion. 2007;47(11):2072–2080.
Diep C, Shih AW, Jamula E, Heddle NM, Parvizian M, Hillis CM. Impact of organizational interventions on reducing inappropriate intravenous immunoglobulin (IVIG) usage: a systematic review and meta‐analysis. Transfus Apher Sci. 2018;57(2):215–221.
Frayha HH, Nuessle SJ, Arishi H, Rayes H, Qunibi WY, Bazarbashi MS. Improving utilization of intravenous immune globulin through concurrent use of an indication form. Eur J Clin Pharmacol. 1997;52(4):255–260.
Tinmouth A, MacDougall L, Fergusson D, Amin M, Graham ID, Hebert PC, et al. Reducing the amount of blood transfused: a systematic review of behavioral interventions to change Physicians' transfusion practices. Arch Intern Med. 2005;165(8):845–852.
Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother. 2000;34(9):1066–1069.
(MSSS) MdlSedSS. Plan de mesures d'urgences du système du sang. 2021.
Pendergrast JM, Sher GD, Callum JL. Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995–2000. Vox Sang. 2005;89(3):150–160.
Perozziello A, Lescure FX, Truel A, Routelous C, Vaillant L, Yazdanpanah Y, et al. Prescribers' experience and opinions on antimicrobial stewardship programmes in hospitals: a French nationwide survey. J Antimicrob Chemother. 2019;74(8):2451–2458.
Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13(1):116.
Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024;143(16):1565–1575.
Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, et al. International recommendations for screening and preventative practices for long‐term survivors of transplantation and cellular therapy: a 2023 update. Transpl Cell Ther. 2024;30(4):349–385.
Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman‐Cribbin A, et al. IVIg use associated with ten‐fold reduction of serious infections in multiple myeloma patients treated with anti‐BCMA bispecific antibodies. Blood Cancer Discov. 2023;4(6):440–451.
McQuilten ZK, Weinkove R, Thao LTP, Crispin P, Degelia A, Dendle C, et al. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy. Blood Adv. 2024;8(7):1787–1795.
Carrillo de Albornoz S, Higgins AM, Petrie D, Irving A, Fanning L, Weinkove R, et al. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies. Blood Adv. 2024;8(9):2259–2267.
Cornblath DR, van Doorn PA, Hartung H‐P, Merkies ISJ, Katzberg HD, Hinterberger D, et al. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022;145(3):887–896.
N'Kaoua E, Attarian S, Delmont E, Campana‐Salort E, Verschueren A, Grapperon AM, et al. Immunoglobulin shortage: practice modifications and clinical outcomes in a reference centre. Rev Neurol (Paris). 2022;178(6):616–623.